在小细胞肺癌中免疫治疗反应的候选生物标志物
Yili Shen1,2, Zhicong Liu1,2, Yi Chen1,2
1Department of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital, Huzhou University, Huzhou, Zhejiang, China.
Current treatment options in oncology
|January 22, 2025
概括
识别生物标志物对于有效的小细胞肺癌免疫疗法至关重要. 本综述探讨了预测患者对这些晚期肺癌治疗反应的潜在生物标志物和挑战.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 生物标志物发现发现
背景情况:
- 小细胞肺癌 (SCLC) 的预后不好,免疫疗法与化疗相结合,作为广泛阶段疾病的标准第一线治疗.
- 虽然有益,但仅有一小部分患者从当前的免疫疗法中经历了长时间的生存.
- 预测患者对免疫疗法的反应仍然是SCLC管理中的重大临床挑战.
研究的目的:
- 审查潜在的生物标志物,以预测小细胞肺癌中对免疫治疗的反应.
- 讨论确定SCLC免疫治疗可靠生物标志物的局限性和挑战.
- 突出分子类型在指导治疗决策中的新兴作用.
主要方法:
- 关于SCLC免疫治疗生物标志物的临床试验和临床前研究的综合文献综述.
- 分析用于小细胞肺癌分子亚型的多omics数据.
- 讨论目前在SCLC生物标志物识别方面的限制.
主要成果:
- 传统的生物标志物不足以指导SCLC的免疫治疗决策.
- 来自多omics数据的新兴分子洞察力为患者分层提供了新的视角.
- 几种潜在的生物标志物正在研究中,尽管尚未确定用于常规临床使用.
结论:
- 迫切需要准确的生物标志物识别,以优化小细胞肺癌患者的免疫疗法选择.
- 了解SCLC分子异质性的进展可能会导致更个性化的治疗策略.
- 克服目前的限制对于改善SCLC免疫疗法的临床结果至关重要.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.